GLP-1 Drugs Like Ozempic May Help Improve Survival and Lower Breast Cancer Recurrence, Study Finds

A New Look at Breast Cancer, Obesity, and Diabetes

Breast cancer remains one of the most common cancers affecting women in the United States. In fact, it makes up 30% of all new female cancer cases each year. Many people do not realize that a breast cancer diagnosis can become even more complicated when a person also lives with obesity or type 2 diabetes. Research has long shown that these conditions can lower survival rates and make the cancer journey harder.

Now, a growing class of medications known as GLP-1 receptor agonists is offering a new reason for hope. Drugs like Ozempic, Wegovy, and Mounjaro have already made headlines for weight loss and diabetes control. A recent study suggests they might also play a role in improving breast cancer outcomes for people with obesity or type 2 diabetes.

What the Study Found

The findings were published in the respected medical journal JAMA Network Open. Researchers looked at data from 841,831 people with breast cancer. The average age of the participants was 69. After setting aside certain cases that did not fit the criteria, the team identified three key groups to study. They wanted to understand how using a GLP-1 drug affected survival and the chance of the cancer coming back.

The numbers were striking. For people with obesity and breast cancer who used a GLP-1 medication, the 5-year survival probability was 97.4%. That means nearly all of them were alive five years after their diagnosis. The 10-year survival probability was 96%. In comparison, those who did not use a GLP-1 drug had a 5-year survival rate of 93.2% and a 10-year survival rate of 88.6%. The use of GLP-1 drugs was also linked to a lower risk of dying from any cause during the 10-year follow-up period.

The researchers also compared GLP-1 drugs to other diabetes treatments. Among participants taking insulin or metformin, the 5-year breast cancer survival rate was 82.3% and the 10-year survival rate was 76.4%. That is much lower than the rates seen in the GLP-1 group. For those with breast cancer and type 2 diabetes who used SGLT2 inhibitors, the 5-year survival rate was 88.9% and the 10-year rate was 73.4%. In the same diabetes group, people using a GLP-1 drug had a 5-year survival rate of 86.3% and a 10-year rate of 75.5%. While the survival benefit appeared stronger when compared to insulin or metformin, it was less dramatic when measured against SGLT2 inhibitors. Still, the GLP-1 group consistently showed lower hazards of all-cause mortality.

Why Obesity and Diabetes Matter in Breast Cancer

Excess body weight is not just a number on a scale. Fat tissue produces estrogen, a hormone that can fuel certain types of breast cancer. This is one reason why carrying extra weight can increase the risk of developing breast cancer in the first place. It also raises the chance that the cancer will return after treatment. Type 2 diabetes adds another layer of risk because high blood sugar and insulin resistance can create an environment in the body that helps cancer cells grow.

For decades, doctors have encouraged cancer patients to maintain a healthy weight and manage blood sugar. However, achieving lasting weight loss through diet and exercise alone is very difficult for many people. GLP-1 medications have changed that picture by helping people lose a significant amount of weight and improve their metabolic health.

How GLP-1 Drugs Could Help Fight Cancer

GLP-1 receptor agonists work by mimicking a natural hormone in the body that controls appetite and blood sugar. They slow down digestion, make you feel full longer, and help the pancreas release insulin when needed. The result is often steady weight loss and better control of diabetes. But the benefits may go deeper. Researchers believe that by reducing body fat, these drugs lower the amount of estrogen produced by fat cells. Improved metabolic health also tamps down chronic inflammation and high insulin levels, both of which are linked to cancer growth.

Lead study author Kristina L. Tatum, PsyD, MS, an instructor in the Department of Social and Behavioral Sciences at the School of Public Health at Virginia Commonwealth University, explained the importance of these findings. “Breast cancer patients with obesity or pre-existing type 2 diabetes often face more complex breast cancer journeys,” she said. “Our findings are encouraging because they suggest that GLP-1RA use may be associated with improved survival and lower recurrence among these patients.”

Dr. Tatum added that while the study cannot prove cause and effect, it gives doctors and patients valuable information to think about as experts continue to explore the possibilities of GLP-1 therapies in cancer survivorship.

What Experts Are Saying

Amy Bremner, MD, a breast surgical oncologist and medical director of breast surgical oncology at MemorialCare Saddleback Medical Center in Laguna Hills, California, who was not involved in the study, called the findings promising. “We know that obesity is well-established as an obesity-associated cancer risk factor. Fat produces estrogen, which promotes certain breast cancer subtypes. By reducing body weight and fat mass, this could potentially reduce recurrence risk,” she said.

However, Dr. Bremner also urged caution. She noted that the study is observational and retrospective, meaning it looks back at existing data rather than setting up a controlled experiment. “Problems with this type of study include selection bias and confounding variables. In addition, could the benefit be a result of factors such as improved metabolic health, weight loss, or even differences in the types of patients selected for these drugs?” she said. In other words, it is possible that people prescribed GLP-1 drugs were already different in some way that helped them do better.

Paunel Vukasinov, MD, a dual board certified internist and obesity medicine specialist at Medical Offices of Manhattan, who also was not involved in the study, pointed to the growing evidence that GLP-1 drugs may have an impact on cancer through better metabolic health. He noted that the survival benefit appeared stronger when compared to insulin or metformin, but less so when compared with SGLT2 inhibitors. “That raises the possibility that improving overall metabolic health may be a major part of what we are seeing,” he said.

Study co-author Bernard F. Fuemmeler, PhD, MPH, professor and Gordon D. Ginder, MD Chair in Cancer Research, said the team was encouraged by the results. “They tell us there is a story here with GLP-1 RAs and cancer survivor outcomes that deserves more attention,” he said. He added that the team plans to continue this work to build a clearer understanding and support both providers and cancer survivors as the science evolves.

A Closer Look at GLP-1 Use in the United States

GLP-1 drugs are no longer a niche treatment. Around 1 in 8 U.S. adults have used a drug like Ozempic, Wegovy, or Mounjaro at some point. This includes 40% of people with diabetes and 25% of those with heart disease. As more people turn to these medications for weight management and diabetes care, understanding their full range of effects becomes critical. The sheer number of users means that even a small benefit—or risk—could affect millions of lives.

This new study adds to a growing body of research that looks beyond weight loss numbers. It hints that these medications might reshape long-term health in ways doctors are only beginning to understand. For breast cancer survivors who already face a higher risk of recurrence because of obesity or diabetes, this is welcome news.

What This Means for Patients Today

If you or a loved one has breast cancer and also lives with obesity or type 2 diabetes, you may wonder if you should ask your doctor about a GLP-1 drug right away. The study does not prove that taking one of these medications will directly prevent cancer from coming back. It shows an association, not a direct cause. But it opens a conversation worth having. Here are some practical takeaways:

• Talk to your oncology team. Share this research with your cancer doctor and your primary care provider. They can help you weigh the potential benefits and risks based on your personal health history.
• Focus on metabolic health. Whether through medication, diet, or exercise, improving blood sugar control and reducing excess body fat can have a positive impact. GLP-1 drugs are one tool among many.
• Consider the whole picture. These medications come with side effects like nausea, vomiting, and in rare cases, more serious issues. They are not right for everyone. A thoughtful conversation with a doctor is essential.
• Stay tuned for more research. Scientists are actively studying how weight loss drugs affect cancer. Future clinical trials may provide stronger evidence on the best way to use them in cancer care.

The Road Ahead

The relationship between obesity, diabetes, and breast cancer is complex. While this large study cannot yet prove that GLP-1 drugs cause better survival, it offers a powerful signal. The 97.4% five-year survival rate for GLP-1 users with obesity and breast cancer, compared to 93.2% for those not using the drug, is hard to ignore. The lower risk of death from any cause over a decade adds more weight to the findings.

Doctors like Dr. Bremner remind us that observational studies have limits. The people who received GLP-1 prescriptions might have had better access to healthcare, healthier lifestyles, or earlier-stage cancers. These confounding factors can muddy the results. That is why researchers like Dr. Fuemmeler and his team are committed to digging deeper. They want to build a clear scientific story that cancer survivors and clinicians can trust.

For now, the message is one of cautious optimism. GLP-1 receptor agonists are proving to be more than just a weight loss trend. They may become an important part of the cancer survivorship toolkit, especially for those facing the double challenge of breast cancer and metabolic disease. As the science continues to unfold, patients and providers can keep these findings in mind when making decisions about long-term health.

Summary

A large study published in JAMA Network Open looked at over 840,000 people with breast cancer. It found that those who used GLP-1 drugs like Ozempic or Wegovy had better survival rates and a lower chance of the cancer returning, particularly

Source: Healthline